Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
We used conditional transgenic mice induced to overexpress GLI1 in the mammary epithelium either alone or in combination with deletion of one Trp53 allele to address the role of elevated GLI1 expression in breast tumour initiation and progression.
|
31219615 |
2020 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
PSL@RES induced apoptosis in breast tumor by upregulation of p53 expression.
|
31746932 |
2020 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Transfection with p21 and p53 tumor suppressor plasmids suppressed breast tumor growth in syngeneic mouse model.
|
30898703 |
2019 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
A total of 787 invasive breast tumors included in a clinically annotated multiethnic population-based tissue microarray (TMA) were screened utilizing commercially available antibodies to p53 and MDM2, and a newly developed monoclonal antibody recognizing MDM2-C.
|
30470976 |
2019 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Here, we show that c-myc is a transcriptional target of p53 in mammary stem cells (MaSCs) and is activated in breast tumors as a consequence of p53 loss.
|
30650356 |
2019 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Loss of p53 caused increased neutrophil levels and systemic inflammation in mice with breast tumors.
|
31399466 |
2019 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages.
|
31637877 |
2019 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The p53 DNA is transported into the nucleus by the aid of the cationic protamine and thus generates expression of the p53 protein that enhances apoptosis combined with CytoC. p53/C-rNC/L-FA is demonstrated to significantly induce tumor cell apoptosis and inhibit tumor growth in the orthotopic breast tumor mouse model.
|
31441204 |
2019 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
For example, we find basal and HER2 positive tumors contain more mutated proteins and more TP53 mutations than luminal A/B breast tumors.
|
31440245 |
2019 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Expression of NBS1, BRCA1, BRCA2, ATM, and p53 was determined by immunohistochemistry in 419 surgically resected breast tumors.
|
30671767 |
2019 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy.
|
31541080 |
2019 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
|
30381462 |
2018 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Nuclear expression of CHEK1 was present in 61% of breast tumours and was associated with tumour size, triple-negative cancer, basal-like phenotype, the epithelial-mesenchymal transition, p53 over-expression, DNA homologous repair pathway dysfunction, and poor prognosis.
|
29075961 |
2018 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
By an in silico approach we identified miR-30a as a putative p53 target and observed that in breast tumors reduced miR-30a expression correlated with p53 inactivation, lymph node positivity and poor prognosis.
|
29666469 |
2018 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In both cohorts, childhood and LFS core cancers, and for women, multiple primary cancers (not multiple breast tumors), were associated with TP53+ results.
|
29529297 |
2018 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
TP53 mutations co-associate with the overexpression of mitotic transcriptional activators, suggesting that these events work together to provide fitness to breast tumors.
|
29847804 |
2018 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Increased global burden of TP53 mutated breast tumors has paved the path for various therapies targeting p53/TP53.
|
30255744 |
2018 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The p53 status is the most probable reason leading to differential LDIR biological activities between breast tumor cells and normal breast cells.
|
27959407 |
2017 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
A direct sequencing analysis of p53 revealed a p.V173M mutation in exon 5 in both the breast tumor and the ovarian cancer.
|
28662703 |
2017 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In addition, in vivo studies in mouse showed that this combination could inhibit the progression of breast tumors through over-expression of p53 and reduction of Ki67 levels.
|
28152473 |
2017 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This study aimed to objectively determine optimal thresholds for p53 positivity by manual and automated scoring methods using whole tissue sections from the Carolina Breast Cancer Study. p53-immunostained slides were available for 564 breast tumors previously assayed for TP53 mutations.
|
26200835 |
2016 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Based on in vivo studies, the growth of breast tumor and expression of CD31, Bcl-2 and nonfunctional p53 were inhibited more effectively by ES-R than by ES-Zn.
|
27693049 |
2016 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
We sequenced p53 in breast tumours from 139 patients and compared this with Δ40p53 and p53 mRNA expression.
|
26586794 |
2016 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Somatic TP53 mutations are the most common genetic event in basal-like breast tumors and TNBC.
|
27149990 |
2016 |